Research compounds Early human study Skin research
Also discussed as: MT-II, MT2
What it is and how it works
Melanotan II is a cyclic analogue of alpha-melanocyte-stimulating hormone investigated for melanotropic effects. Its receptor activity can affect more than pigmentation. A visible change in skin color is therefore not a complete measure of benefit or safety.
Source for the mechanism context →A closer look at the cited evidence
Early human study
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- Dorr et al., 1996 — Melanotan II pilot phase 1 study
- Design
- Small placebo-controlled pilot exposure study.
- Who or what was studied
- Three male volunteers.
- What was observed
- The pilot investigated pigmentation effects and reported symptoms including nausea and sleepiness.
- Limits of interpretation
- Three participants cannot define uncommon harms or establish a safe tanning treatment. This early study cannot validate contemporary online products.
What the evidence means
A change in pigmentation is not proof of a safe cosmetic intervention.
Approval and regulatory context
Not an FDA-approved tanning medicine.
Safety and uncertainty
Serious adverse events have been reported.
What remains uncertain
A pigmentation effect is not evidence of protection from sunlight or of long-term dermatologic safety. A credible clinical claim would need much more than a small early exposure experiment.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.